{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T20:45:18Z","timestamp":1648759518595},"reference-count":24,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2006,8,1]],"date-time":"2006-08-01T00:00:00Z","timestamp":1154390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2006,8]]},"DOI":"10.1016\/j.lungcan.2006.04.010","type":"journal-article","created":{"date-parts":[[2006,6,20]],"date-time":"2006-06-20T11:26:11Z","timestamp":1150802771000},"page":"165-170","source":"Crossref","is-referenced-by-count":0,"title":["Dose-finding study of fixed dose gemcitabine and escalating doses of ifosfamide given on days 1 and 8 in patients with advanced non-small cell lung cancer"],"prefix":"10.1016","volume":"53","author":[{"given":"S.","family":"Baka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Manegold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Buchholz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Schott-von-R\u00f6mer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Lorigan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Nagel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Blackhall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Aschroft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Thatcher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2006.04.010_bib1","first-page":"1351","article-title":"Phase I dose-finding study of gemcitabine and ifosfamide in advanced NSCLC","volume":"14","author":"Eberhard","year":"1995","journal-title":"Proc Amer Soc Clin Oncol"},{"key":"10.1016\/j.lungcan.2006.04.010_bib2","first-page":"15","article-title":"Ifosfamide and gemcitabine: a phase II trial in advanced inoperable non-small cell lung cancer","volume":"25","author":"Gatzemeier","year":"1998","journal-title":"Semin Oncol"},{"key":"10.1016\/j.lungcan.2006.04.010_bib3","first-page":"5651","article-title":"Cisplatin\u2013carboplatin\u2013gemcitabine or ifosfamide\u2013gemcitabine in advanced non-small cell lung cancer carcinoma: two pilot studies","volume":"19","author":"Berghmans","year":"1999","journal-title":"Anticancer Res"},{"issue":"3","key":"10.1016\/j.lungcan.2006.04.010_bib4","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1200\/JCO.1999.17.3.914","article-title":"Front-line treatment of advanced non-small cell lung cancer (NSCLC) with docetaxel (D) and gemcitabine (G): a multicenter phase II trial","volume":"17","author":"Georgoulias","year":"1999","journal-title":"JCO"},{"issue":"1","key":"10.1016\/j.lungcan.2006.04.010_bib5","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.lungcan.2004.03.007","article-title":"Docetaxel and Gemcitabine administered on days 1 and 8 for metastatic non-small cell lung carcinoma (NSCLC): a phase II multicenter trial","volume":"46","author":"Hirsh","year":"2004","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2006.04.010_bib6","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0169-5002(01)00417-2","article-title":"Comparison of docetaxel\/cisplatin to docetaxel\/gemcitabine as first-line treatment for advanced non-small cell lung cancer: early results of a randomized trial","volume":"34","author":"Georgoulias","year":"2001","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2006.04.010_bib7","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1200\/JCO.2002.12.112","article-title":"Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small cell lung cancer: a phase III randomized trial","volume":"20","author":"Kosmidis","year":"2002","journal-title":"JCO"},{"issue":"1","key":"10.1016\/j.lungcan.2006.04.010_bib8","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0169-5002(02)00145-9","article-title":"Phase II study of weekly gemcitabine and paclitaxel in patients with previously untreated stage IIIb and IV non-small cell lung cancer","volume":"38","author":"Bhatia","year":"2002","journal-title":"Lung Cancer"},{"issue":"12","key":"10.1016\/j.lungcan.2006.04.010_bib9","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1093\/annonc\/mdf308","article-title":"Phase I\/II study of paclitaxel, gemcitabine and vinorelbine as first-line chemotherapy of non-small-cell lung cancer","volume":"13","author":"Lorusso","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.lungcan.2006.04.010_bib10","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1200\/JCO.1999.17.10.3188","article-title":"Mitomycin, ifosfamide, and cisplatin in unrespectable non-small cell lung cancer: effects on survival and quality of life","volume":"17","author":"Cullen","year":"1999","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.lungcan.2006.04.010_bib11","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/cncr.11535","article-title":"Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced non-small cell lung carcinoma","volume":"98","author":"Danson","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2006.04.010_bib12","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1200\/JCO.2005.03.037","article-title":"Gemcitabine plus carboplatin versus mitomycin, ifosfamide and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized Study of the London Lung Cancer Group","volume":"1","author":"Rudd","year":"2005","journal-title":"JCO"},{"key":"10.1016\/j.lungcan.2006.04.010_bib13","first-page":"28","article-title":"Epirubicin and ifosfamide in metastatic breast cancer","volume":"23","author":"Becher","year":"1996","journal-title":"Semin Oncol"},{"key":"10.1016\/j.lungcan.2006.04.010_bib14","first-page":"3","article-title":"Gemcitabine: metabolism, mechanism of action, and self-potentiation","volume":"22","author":"Plunkett","year":"1995","journal-title":"Semin Oncol"},{"key":"10.1016\/j.lungcan.2006.04.010_bib15","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1200\/JCO.1994.12.8.1527","article-title":"Gemcitabine: current status of phase I and II trials","volume":"12","author":"Kaye","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2006.04.010_bib16","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/0959-8049(95)00444-0","article-title":"Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study","volume":"32","author":"Gatzemeier","year":"1996","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.lungcan.2006.04.010_bib17","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1200\/JCO.1994.12.8.1535","article-title":"Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study","volume":"12","author":"Abratt","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2006.04.010_bib18","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1200\/JCO.1994.12.9.1821","article-title":"Single-agent activity of weekly gemcitabine in advanced non-small cell lung cancer: a phase II study","volume":"12","author":"Anderson","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2006.04.010_bib19","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00001813-199512006-00004","article-title":"Phase II trials of single-agent activity of gemcitabine in patients with advanced non-small cell lung cancer: an overview","volume":"6","author":"Shepherd","year":"1995","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.lungcan.2006.04.010_bib20","first-page":"1825","article-title":"A late phase II study of gemcitabine (LY 188011) against non-small cell lung cancer","volume":"23","author":"Fukuoka","year":"1996","journal-title":"Jpn J Cancer Chemother"},{"key":"10.1016\/j.lungcan.2006.04.010_bib21","first-page":"1681","article-title":"A late phase II study of gemcitabine (LY 188011) against non-small cell lung cancer","volume":"23","author":"Yokayama","year":"1996","journal-title":"Jpn J Cancer Chemother"},{"issue":"S2","key":"10.1016\/j.lungcan.2006.04.010_bib22","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000073359","article-title":"Ifosfamide in non-small cell lung cancer","volume":"65","author":"Boni","year":"2003","journal-title":"Oncology"},{"key":"10.1016\/j.lungcan.2006.04.010_bib23","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1023\/A:1008207731111","article-title":"Single-agent gemcitabine versus cisplatin\/etoposide. Early results of a randomized phase II study in locally advanced or metastatic non-small cell lung cancer","volume":"8","author":"Manegold","year":"1997","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.lungcan.2006.04.010_bib24","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1586\/14737140.4.3.345","article-title":"Gemcitabine (Gemzar) in non-small cell lung cancer","volume":"4","author":"Manegold","year":"2004","journal-title":"Expert Rev Anticancer Ther"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500206002145?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500206002145?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,19]],"date-time":"2019-04-19T12:53:06Z","timestamp":1555678386000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500206002145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["S0169500206002145"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2006.04.010","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2006,8]]}}}